Boston Scientific Corporation (NYSE:BSX) is reporting second quarter financial results on Wednesday 29th July 2020, before market open.
According to analysts surveyed by Thomson Reuters, BSX is expected to report 2Q20 loss of $ 0.02 per share from revenue of $ 1730.33 million.
For the full year, analysts anticipate top line of $ 9755.21 million, while looking forward to income of $ 0.96 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 11,809.00 million ~ $ 12,023.00 million, where as bottomline are predicted in a range of $ 1.74 ~ $ 1.79 per share
Click Here For More Historical Outlooks Of Boston Scientific Corporation
Previous Quarter Performance
Boston Scientific Corporation disclosed income for the first quarter of $ 0.28 per share, from the revenue of $ 2,543.00 million. The quarterly earnings dropped 20.00 percent while revenues surged 2.01 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.31 per share from $ 2521.13 million in revenue. The bottom line results missed street analysts by $ 0.03 or 9.68 percent, at the same time, top line results outshined analysts by $ 21.87 million or 0.87 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Boston Scientific Corporation
Stock Performance
According to the previous trading day, closing price of BSX was $ 38.27, representing a 58.80 % increase from the 52 week low of $ 24.10 and a 17.91 % decrease over the 52 week high of $ 46.62.
The company has a market capital of $ 54.68 billion and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”BSX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Boston Scientific Corporation will be hosting a conference call at 8:00 AM eastern time on 29th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.bostonscientific.com
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.